


# Treatment Options and Working with Your Doctor

Borna Bonakdarpour, MD, FAAN


Assistant Professor of Neurology  
Cognitive Neurology and Alzheimer's Disease Center  
Department of Neurology  
Northwestern University Feinberg School of Medicine  
Twitter: @bbonakda




# Multidisciplinary Management



# Clinical Diagnosis



# Underlying Causes



# Treatment of FTD Spectrum

- **Standard Treatments**

- Pharmacologic treatments

- No FDA approved drug
- Based on open-label or case series
- Symptomatic treatment
  - Behaviors: SSRIs: Paroxetine, Citalopram, Trazodone  
Antipsychotics: Quetiapine, Olanzapine  
Antiepileptics: Valproic acid,  
Carbamazepine
  - Cognition: Galantamine for PPA (Kertesz et al., 2008)

# Treatment of FTD Spectrum

- **Standard Treatments**

- Non-pharmacologic interventions (Merrilees et al., 2007)
  - Reward based therapy
  - Cognitive therapy
  - Speech and language therapy
  - Physical therapy
  - Life enrichment and strength-based intervention

# FTLD Clinical Trials

- **Tau stabilization**

- **Devunetide (Boxer et al., 2014)**

- Phase 2/3 trial
- 313 PSP participants
- Showed that a large multicenter international clinical trial in FTD is feasible

- **Inhibit tau aggregation**

- **Leuco-methylthioninium, LMTM, or Methylene Blue (Wischik et al. 2016)**

- Phase 3 trial
- 221 patients with FTD
- The study could have benefitted from spinal fluid exam to rule out Alzheimer disease for participant selection.

# FTLD Clinical Trials

## - Increase progranulin

- Nimodipine (Miller, IC-FTD 2016):

- 8-week, open-label, dose-finding study for the treatment of progranulin insufficiency from GRN gene mutation

- Primary outcome: plasma and CSF progranulin

- Strong patient selection criteria (patients with known mutation)



# FTLD Clinical Trials

## - Recruiting (26 trials)

- **AADvac 1** (anti-tau vaccine) for PPA-G
- **tDCS** for bvFTD and PPA
- **Low dose lithium** for behavioral symptoms of bvFTD
- **Biomarker studies** more importantly Tau-PET
- **GENFI** (Genetic FTD Initiative)
- **ARTFL** (Advancing research and Treatment for Frontotemporal Lobar Degeneration)